Two unusual cases from the United States have prompted doctors to warn of possible mental health issues following the abrupt cessation of therapy with one of the drugs used for diabetes and obesity. The drug in question is tirzepatide, known by the brand names Mounjaro and Zepbound. Two men were hospitalised after stopping the medication, with doctors recording psychotic symptoms in one and a manic episode in the other.

The cases were described in the specialist journal The Primary Care Companion for CNS Disorders. The authors emphasise that a conclusion cannot be drawn from just two cases that stopping therapy caused the mental disorders, but they believe the temporal association warrants further investigation.

The first case concerns a 61-year-old man who was admitted to hospital in October 2025 due to increasing confusion and unpredictable behaviour. The man reported worsening depression, paranoia, and auditory and visual hallucinations. He developed a rare psychiatric symptom known as Cotard’s delusion, a condition in which individuals may believe they are dead or that parts of their body do not exist or no longer function. Doctors determined that the man had stopped taking tirzepatide in August of the same year due to nausea, and he had previously been diagnosed with depression.

The second case involves a 52-year-old man who also sought hospital care in October 2025 due to sudden mood changes and unusual behaviour. Doctors diagnosed him with a manic episode, with symptoms including extremely rapid and incoherent speech, an excessively high opinion of his own abilities, impulsivity, and irritability. The man stated that he had abruptly stopped taking tirzepatide a month earlier. During six months, he lost approximately 45 kilograms, and in the weeks before hospitalisation, he had increased his cannabis consumption. He was also found to have low levels of vitamin B12 and had a previously diagnosed anxiety disorder. Following examination, he was transferred to a psychiatric facility for further treatment.

Drugs in the GLP-1 receptor agonist class act on systems involved in regulating blood sugar and appetite. GLP-1 receptors are also found in the brain, and research suggests that some of these drugs may cross the blood-brain barrier. The effects of these drugs on brain processes, particularly after cessation of use, are not yet fully understood.

The authors of the medical report consider it possible that stopping therapy in a small number of susceptible patients may contribute to the onset of mood disorders or psychotic symptoms. They specifically highlight patients with nutritional deficiencies, such as the second man who was found to have low vitamin B12 levels. A previous analysis of a European adverse event reporting database recorded 481 reports of psychiatric events associated with semaglutide, liraglutide, and tirzepatide, accounting for slightly more than one per cent of the total number of reported events linked to these drugs. The reporting of an adverse event does not prove that the drug caused it.

The authors of the new report warn that the potential psychiatric effects of stopping these drugs are still poorly studied. The sudden onset of mood disorders or psychotic symptoms after discontinuing GLP-1 receptor agonists could represent an under-recognised clinical phenomenon, the authors believe. Doctors should consider recent changes in therapy when assessing patients with newly developed psychiatric symptoms. However, the two cases do not prove that abrupt cessation of tirzepatide causes psychosis or mania, nor do they indicate how frequent such a reaction might be.